ArticleTherapeutic advances in medical oncology2025
Options after progression on first-line CDK4/6 inhibitors in advanced breast cancer patients.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Elevated thymidine kinase 1 expression at baseline predicts poor prognosis in breast cancer patients.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.EClinicalMedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is no recognized optimal second-line treatment option for advanced hormone receptor-positive (HR+) breast cancer patients with CDK4/6 inhibitor (CDK4/6i) resistance. Objectives: This work aims to identify the optimal treatment option by evaluating the efficacy of various second-line treatment options in CDK4/6i-pretreated HR+ advanced breast cancer. Subgroup analyses aim to discuss how different genetic backgrounds and clinical characteristics influence the efficacy. Design: A systematic review and network meta-analysis (NMA) was designed. Data sources and methods: A comprehensive search was conducted in Medline, Embase, and Cochrane Library for randomized controlled trials (RCTs). The primary outcome was progression-free survival (PFS), with subgroup analysis based on visceral metastasis and ESR1 mutations. Secondary outcomes were overall survival (OS), overall response rate (ORR), and clinical benefit rate (CBR). Bayesian NMA was conducted using GeMTC in R, with hazard ratios and 95% confidence intervals as effect measures. Results: Our analysis included 19 clinical trials involving 13 different treatment regimens ( Conclusion: Our analysis reveals CDK4/6i + Ful is the most effective treatment option for CDK4/6i-pretreated HR+ advanced breast cancer, particularly in patients with visceral metastases or ESR1 mutations. In addition, Bcl-2i + Ful and SERD may be potential second-line strategy options. Trial registration: This meta-analysis was registered in PROSPERO (CRD42024518926).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.